Close Menu

NEW YORK — Selux Diagnostics said on Wednesday that it has met the first milestone in its antimicrobial susceptibility test (AST) development contract with the Biomedical Advanced Research and Development Authority (BARDA), triggering an $11.4 million payment.

The Boston-based company said it will use the new funding to advance its Next-Generation Phenotyping (NGP) test — an automated, high-throughput AST designed to provide results within 12 to 24 hours — through clinical trials.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Mar
18
Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Mar
29
Sponsored by
Thermo Fisher Scientific

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.